PSTV
Price:
$1.08
Market Cap:
$6.37M
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Au...[Read more]
Industry
Biotechnology
IPO Date
2001-07-11
Stock Exchange
NASDAQ
Ticker
PSTV
According to Plus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.46. This represents a change of -37.47% compared to the average of -0.74 of the last 4 quarters.
The mean historical PE Ratio of Plus Therapeutics, Inc. over the last ten years is -0.75. The current -0.46 PE Ratio has changed 6.01% with respect to the historical average. Over the past ten years (40 quarters), PSTV's PE Ratio was at its highest in in the September 2015 quarter at 8.56. The PE Ratio was at its lowest in in the December 2015 quarter at -2.96.
Average
-0.75
Median
-0.66
Minimum
-1.43
Maximum
-0.20
Discovering the peaks and valleys of Plus Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 267.04%
Maximum Annual PE Ratio = -0.20
Minimum Annual Increase = -81.38%
Minimum Annual PE Ratio = -1.43
Year | PE Ratio | Change |
---|---|---|
2023 | -0.41 | 2.38% |
2022 | -0.40 | -54.48% |
2021 | -0.89 | -7.43% |
2020 | -0.96 | 267.04% |
2019 | -0.26 | 30.65% |
2018 | -0.20 | -53.41% |
2017 | -0.43 | -63.83% |
2016 | -1.18 | -17.00% |
2015 | -1.43 | 4.32% |
2014 | -1.37 | -81.38% |
The current PE Ratio of Plus Therapeutics, Inc. (PSTV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.57
5-year avg
-0.58
10-year avg
-0.75
Plus Therapeutics, Inc.’s PE Ratio is less than Aditxt, Inc. (-0.00), less than Palisade Bio, Inc. (-0.18), less than Revelation Biosciences, Inc. (-0.05), less than Quoin Pharmaceuticals, Ltd. (-0.28), greater than Zura Bio Limited (-4.76), less than Altamira Therapeutics Ltd. (-0.02), greater than Immix Biopharma, Inc. (-2.93), less than Enveric Biosciences, Inc. (-0.27), less than First Wave BioPharma, Inc. (-0.29), less than Dermata Therapeutics, Inc. (-0.18), less than Panbela Therapeutics, Inc. (-0.06), less than ContraFect Corporation (-0.00), greater than Protara Therapeutics, Inc. (-2.75), less than Vaccinex, Inc. (-0.13), greater than Monopar Therapeutics Inc. (-0.59), greater than Miromatrix Medical Inc. (-7.13), greater than Surrozen, Inc. (-0.89), less than Avenue Therapeutics, Inc. (-0.20), greater than Hoth Therapeutics, Inc. (-0.72), greater than NeuroBo Pharmaceuticals, Inc. (-0.87), greater than Virax Biolabs Group Limited (-0.57),
Company | PE Ratio | Market cap |
---|---|---|
-0.00 | $2.62M | |
-0.18 | $4.73M | |
-0.05 | $2.51M | |
-0.28 | $2.45M | |
-4.76 | $151.48M | |
-0.02 | $1.13M | |
-2.93 | $59.97M | |
-0.27 | $3.15M | |
-0.29 | $5.99M | |
-0.18 | $2.73M | |
-0.06 | $1.67M | |
-0.00 | $0 | |
-2.75 | $177.43M | |
-0.13 | $3.16M | |
-0.59 | $116.38M | |
-7.13 | $92.95M | |
-0.89 | $39.78M | |
-0.20 | $3.53M | |
-0.72 | $5.43M | |
-0.87 | $20.33M | |
-0.57 | $7.47M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Plus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Plus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Plus Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Plus Therapeutics, Inc. (PSTV)?
What is the highest PE Ratio for Plus Therapeutics, Inc. (PSTV)?
What is the 3-year average PE Ratio for Plus Therapeutics, Inc. (PSTV)?
What is the 5-year average PE Ratio for Plus Therapeutics, Inc. (PSTV)?
How does the current PE Ratio for Plus Therapeutics, Inc. (PSTV) compare to its historical average?